摘要
目的观察卡维地洛联合缬沙坦胶囊治疗伴有冠心病的高血压患者临床疗效。方法将68例伴有冠心病的高血压患者分为2组,治疗组(采用卡维地洛联合缬沙坦胶囊治疗)34例,对照组(采用卡维地洛治疗)34例,2组治疗均为12周。对治疗前后的血压、心率及冠心病的临床指标进行监测评价。结果治疗12周后所有患者收缩压和舒张压、24h心绞痛发作的频率、持续时间、心肌缺血总负荷(TIB),都有所下降(P<0.05),治疗组较对照组下降更明显(P<0.05),与治疗前比较差异有统计学意义。结论卡维地洛联合缬沙坦胶囊协同降压对于伴有冠心病的高血压患者临床疗效好,不良反应低,安全性好。
Objective To observe clinical curative effect of coronary heart disease （CHD） patients with high blood pressure using carvedilol combined valsartan capsules. Methods 68 cases of coronary heart disease （CHD） patients with high blood pressure are divided into two groups, the treatment group （using carvedilol combined valsartan cap- sules） ,34 cases, and control group （treated with carvedilol） ,34 cases, 2 groups are treated for 12 weeks. Clinical indi- cators of Blood pressure, heart rate and coronary heart disease （CHD） before and after the treatment are monitored and evaluated. Results After 12 weeks treatment, patients＇ systolic blood pressure and diastolic blood pressure, and 24 h angina frequency, duration, and total load （ TIB）, myocardial is chemia is decreased （ P 〈 0.05 ）, The treatment group decreased more significantly （ P 〈 0. 05 ）. than the control group the difference was statistically significant compared with previous treatment. Conclusions There is good clinical curative effect low on heathy reaction and good safety to coro- nary heart disease （CHD） patients with high blood pressure using carvedilol combined valsartan capsule synergy.
出处
《航空航天医学杂志》
2015年第6期671-673,共3页
Journal of Aerospace medicine
关键词
卡维地洛
缬沙坦胶囊
冠心病
原发性高血压
carvedilol valsartan capsules coronary heart disease （CHD） Primary hypertension
